Maria A.
- Country
- Spain
- Department
- Medical Oncology
Research Overview
- Pumitamig plus Combination Therapy Versus Nivolumab plus Combination Therapy in Previously Untreated Advanced or Metastatic Gastric, GEJ, or Esophageal Adenocarcinoma
- Phase II Study of Total Neoadjuvant Durvalumab Plus FLOT Combination Therapy Followed by Postoperative Durvalumab in Resectable Gastroesophageal Adenocarcinoma
- Phase 3 Randomized Study of Trastuzumab Deruxtecan vs. Ramucirumab and Paclitaxel in HER2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Data & Insights
Has run more than one trial at 87 of 231 partner sites.
Specializations
Hematologic Malignancies
Investigator concentrates on malignant blood disorders such as Acute Myeloid Leukemia, Myelodysplastic Syndromes, Multiple Myeloma, and aggressive lymphomas including Diffuse Large B‑Cell Lymphoma and Chronic Lymphocytic Leukemia.
- Targeted agents for AML and high‑risk MDS
- Immunomodulatory regimens for relapsed myeloma
- Combination therapies for refractory B‑cell lymphomas
Efforts aim to extend survival and achieve deeper remissions in high‑risk hematologic cancers.
Solid Tumor Oncology
Research spans major solid cancers, notably Breast Cancer, Non‑Small Cell Lung Cancer, Colorectal Cancer, Gastric Cancer, Ovarian Cancer and Head and Neck Squamous Cell Carcinoma.
- Biomarker‑driven therapies for HER2‑negative breast disease
- KRAS‑mutant targeted approaches in NSCLC
- Immunotherapy combinations for advanced gastrointestinal tumors
Focus is on precision oncology to improve response rates across diverse tumor types.
Autoimmune and Inflammatory Disorders
Investigator engages with systemic immune conditions such as Systemic Lupus Erythematosus, Systemic Sclerosis, Idiopathic Inflammatory Myopathy, ANCA‑Associated Vasculitis, as well as common allergic diseases like Atopic Dermatitis and Asthma.
- Biologic modulation of lupus activity
- Anti‑fibrotic strategies for scleroderma
- Cytokine inhibition in severe myopathies
Goal is to mitigate organ damage and enhance quality of life in chronic autoimmune diseases.
Cardiovascular and Metabolic Diseases
Clinical work includes cardiovascular emergencies and chronic risk factors such as Acute Coronary Syndrome, Heart Failure, Atrial Fibrillation, Hypertension, Type 2 Diabetes Mellitus, Severe Hypertriglyceridemia and broader Atherosclerotic Cardiovascular Disease.
- Cardioprotective agents post‑myocardial infarction
- SGLT2‑inhibitor trials in heart failure with preserved ejection fraction
- Lipid‑lowering therapies for hypertriglyceridemia
Research seeks to reduce cardiovascular events and improve metabolic health.
Neurological and Neurodegenerative Conditions
Investigator addresses neuro‑degeneration and seizure disorders, including Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, Parkinson’s Disease, Epilepsy and Multiple System Atrophy.
- Antibody‑based disease‑modifying therapies for AD
- Neuroprotective approaches in ALS
- Novel dopaminergic strategies for Parkinsonian motor symptoms
Efforts aim to slow disease progression and improve neurological function.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
